No Data
No Data
Express News | Synaptogenix Announces New Collaboration With Lsu Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix Price Target Announced at $14.00/Share by Maxim Group
Maxim Group Upgrades Synaptogenix to Buy, Announces $14 Price Target
Synaptogenix Analyst Ratings
Maxim Group Upgrades Synaptogenix(SNPX.US) to Buy Rating, Announces Target Price $14
Maxim Group analyst Jason McCarthy upgrades $Synaptogenix(SNPX.US)$ to a buy rating, and sets the target price at $14.According to TipRanks data, the analyst has a success rate of 24.0% and a total
Express News | Synaptogenix Inc : Maxim Group Raises to Buy From Hold
No Data